Abstract Number: 552 • 2015 ACR/ARHP Annual Meeting
The Relationship Between Efficacy and Toxicity in Patients with Rheumatoid Arthritis Receiving Methotrexate in Combination with Adalimumab
Background/Purpose: Combination treatment of rheumatoid arthritis (RA) with methotrexate (MTX)+adalimumab (ADA) has been shown to be more effective than ADA monotherapy. However, MTX is associated…Abstract Number: 2868 • 2015 ACR/ARHP Annual Meeting
Relative Efficacy of Adalimumab Versus Secukinumab in Active Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
Background/Purpose: The phase 3 FUTURE 1 and FUTURE 2 trials demonstrated efficacy of secukinumab (SEC) for active psoriatic arthritis (PsA). However, there is limited data…Abstract Number: 589 • 2015 ACR/ARHP Annual Meeting
Adalimumab Concentration at 16 Weeks of Treatment Is Associated with Treatment Discontinuation within One Year
Background/Purpose: Anti-drug antibodies (ADAb) in patients treated with adalimumab have been associated with decreased adalimumab concentrations and loss of clinical response, and therefore treatment discontinuation.…Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…Abstract Number: 598 • 2015 ACR/ARHP Annual Meeting
Economic Impact of Decreasing Adalimumab and Etanercept Doses and Drug Monitoring in Patients with Rheumatoid Arthritis in Clinical Remission: Preliminary Study from a Local Biologics Unit
Background/Purpose: To evaluate the economic impact of adalimumab (ADL) and etanercept (ETN) dose reduction (by decreasing treatment frequency) and drug monitoring in patients with rheumatoid…Abstract Number: 612 • 2015 ACR/ARHP Annual Meeting
Thromboembolic Events Are Not Associated with Anti-Adalimumab Antibodies
Background/Purpose: Treatment of rheumatoid arthritis (RA) with anti-Tumor Necrosis Factor (TNF) such as adalimumab may result in some patients (pts) developing anti-adalimumab antibodies (AAA). Findings…Abstract Number: 651 • 2015 ACR/ARHP Annual Meeting
The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis
Background/Purpose: Minimal disease activity (MDA)1 is a clinically meaningful and comprehensive treatment target for psoriatic arthritis (PsA). The purpose was to determine if baseline (BL)…Abstract Number: 2036 • 2015 ACR/ARHP Annual Meeting
Infliximab Versus Adalimumab in Severe Uveitis: Multicenter Study from the French Uveitis Network
Background/Purpose: Anti-tumour necrosis factor (TNF) molecules have become a valuable addition to the therapeutic armamentarium for patients with severe uveitis. However, direct comparison of safety…Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…Abstract Number: 2427 • 2014 ACR/ARHP Annual Meeting
Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis
Background/Purpose: Although available data has suggested successful withdrawal of a monoclonal antibody TNF blocker after achieving low disease activity (LDA) or remission over the short-term…Abstract Number: 500 • 2014 ACR/ARHP Annual Meeting
Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement
Background/Purpose Dose reduction and discontinuation of TNF inhibitors (TNFi) is feasible in many rheumatoid arthritis (RA) patients, but leads to (temporary) worsening of disease activity…Abstract Number: 2393 • 2014 ACR/ARHP Annual Meeting
Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab
Background/Purpose Methotrexate (MTX) is used in monotherapy or in combination with other DMARDs in the treatment of patients (pts) with rheumatoid arthritis (RA). We evaluated…Abstract Number: 490 • 2014 ACR/ARHP Annual Meeting
A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis – an Interim Analysis
Background/Purpose Rheumatoid arthritis (RA) is associated with elevated cardiovascular (CV) risk not explained by traditional risk factors. Increased CV risk may develop prior to the…Abstract Number: 2043 • 2014 ACR/ARHP Annual Meeting
How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists?
Background/Purpose: During the development of algorythms for screening latent tuberculosis before starting TNF-alpha antagonists, it is assumed that BCG vaccination causes false positive PPD and…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 17
- Next Page »